Téléthon Controversy Erupts as Singer Accusations Surface
Paris,France – November 26,2025 – A dispute involving popular French singers Vitaa and Slimane has cast a shadow over preparations for the annual Téléthon fundraising event,with accusations surfacing that a Niçoise Santa Claus figure interfered with their participation. France Télévisions swiftly denied claims that the event’s institution was altered to appease personal grievances.
The controversy centers on allegations that the Santa, identified only as a local personality, leveraged influence to disrupt a planned appearance by Vitaa and Slimane, diverting resources initially intended for supporting sick children. This action,according to sources,stemmed from a personal disagreement and prioritized ego over the Téléthon’s core mission. The incident has sparked outrage, raising questions about the integrity of the event and the potential for personal conflicts to undermine charitable efforts.
The Téléthon, a nationally televised fundraising marathon, is critical for supporting research into rare diseases and providing assistance to affected families. In 2024, the event achieved a record fundraising total of over 96 million euros-the highest amount collected sence 2016-demonstrating its significant impact. This year’s event aims to build on that success, but the current dispute threatens to distract from the vital cause.
Slimane, a frequent performer at Téléthon events and sponsor of the “Juste humain” association dedicated to hospitalized children’s well-being, recently sold 20,000 tickets in hours for ten concerts at Salle Pleyel. Vitaa has also been a consistent supporter of the Téléthon.
france Télévisions maintains that the Téléthon’s focus remains firmly on solidarity with sick children. Saïd Boussif’s observation,”time always ends up restoring order. And he does it very well,” underscores the hope that the situation will be resolved and not detract from the event’s primary objective. Organizers are proceeding with preparations, emphasizing the importance of maintaining public support for research into rare diseases.
